clinical Trials

• Tyligand Announces First Patient Dosed for Phase 1 Trial of TSN084, A Multi-Kinase Inhibitor to Address Tumor Resistance of Targeted Therapies
• Tyligand Bioscience Announces First Patient Dosed for the Phase 1 Trial of TSN222，the Global First Dual Action Tumor Immune Agonist
• Tyligand Bioscience Announces First Patient Dosed in Phase 1/2 Clinical Trial of TSN1611, a Selective and Orally Bioavailable KRAS G12D Inhibitor
• Tyligand Bioscience Receives Clinical Trial Clearance from U.S. FDA and China NMPA for Dual Function Immune Agonist TSN222
• Tyligand Bioscience Receives IND Clearance from China NMPA for TSN084, a Multi-kinase Inhibitor to Address Tumor Resistance to Targeted Therapies
• Tyligand Bioscience Receives IND Clearance from U.S. FDA for TSN084, a Multi-kinase Inhibitor to Address Tumor Resistance to Targeted Therapies
• Tyligand Bioscience to Present Preclinical Study Results of TSN1611, a potent, selective, and orally bioavailable KRAS G12D Inhibitor at AACR 2024, following FDA’s IND Clearance